New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
11:40 EDTZIOP, THLDThreshold higher after Ziopharm terminates STS drug development
Threshold Pharmaceuticals (THLD) shares are trading higher today after rival cancer drug discovery company Ziopharm (ZIOP) terminated its development of palifosfamide. WHAT'S NEW: Earlier today, Ziopharm announced that its Phase 3 trial of palifosfamide for the treatment of metastatic soft tissue sarcoma, or STS, in the first-line setting did not meet its primary endpoint of progression-free survival. Like Ziopharm, Threshold focuses on the discovery and development of cancer therapeutics and is also in the process of evaluating a drug to treat patients with soft tissue sarcoma with its development of TH-302. WHAT'S NOTABLE: Threshold's TH-302 is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma and the other in combination with gemcitabine versus gemcitabine and placebo in patients with advanced pancreatic cancer. Both Phase 3 trials are being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TODAY'S PRICE ACTION: Shares of Threshold Pharmaceuticals are up 11c, or 2.3% to $4.90 in late morning trading. Meanwhile, shares of Ziopharm, which were downgraded by at least four analyst firms after its announcement, plunged 62% to $1.94.
News For THLD;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
08:04 EDTZIOPZiopharm announces initiation of Phase 1b/2 study of Ad-RTS-hIL-12 gene therapy
Subscribe for More Information
April 22, 2015
08:13 EDTTHLDThreshold: data suggest TH-4000 may overcome conventional EGFR-TKIs resistance
Subscribe for More Information
April 20, 2015
17:04 EDTZIOPOn The Fly: Top stock stories for Monday
Stocks on Wall Street were higher for the day, beginning the session sharply higher and remaining in positive territory throughout. China’s central bank announced a reduction in bank reserve requirements in an effort to increase liquidity and spur economic growth within the country. Following the open, the market moved in a relatively narrow range as investors await the latest round of earnings reports for one of the season's heavier weeks. ECONOMIC EVENTS: In the U.S., the Chicago Fed National Activity Index came in at 0.42 versus expectations for positive 0.1. In Asia, the People's Bank of China lowered its reserve requirement ratio, by 1 percentage point, the lowest since the financial crisis. Despite this, the Shanghai Composite Index fell 1.6% because regulators had already begun curbing speculative trading on Friday. COMPANY NEWS: Morgan Stanley (MS) advanced 0.57%, or 21c, to $36.96 after reporting earnings prior to the market open. The bank beat on both EPS and revenue, and also raised its dividend to 15c from 10c. CEO James Gorman was pleased with the quarter and cited growth across the majority of the company's operations. MAJOR MOVERS: Among the notable gainers was Hasbro (HAS), which rose 12.55% to end the session at $74.16 after reporting EPS and revenue in excess of analyst expectations. During its earnings conference call, the company appeared confident on its 2015 offerings which include Disney (DIS) Princess and Frozen product lines. Also higher was Rovi (ROVI), gaining 8.64% to close the day at $19.11 after renewing its licensing and program guide agreement with Charter (CHTR). Among the noteworthy losers was Caesars Entertainment (CZR), tumbling 17.01% to $10 after failing to reach an agreement on its restructuring. Also lower were a number of medical companies involved in the development of CAR-T cancer therapies, including Kite Pharma (KITE), Juno Therapeutics (JUNO), blue bird bio (BLUE), and ZIOPHARM Oncology (ZIOP). The drop followed disappointing, small-scale studies presented during the annual meeting of the American Association for Cancer Research. INDEXES: The Dow rose 208.63, or 1.17%, to 18,034.93, the Nasdaq advanced 62.79, or 1.27%, to 4,994.6, and the S&P 500 gained 19.22, or 0.92%, to 2,100.4.
12:31 EDTZIOPOn The Fly: Top stock stories at midday
Stocks on Wall Street were higher at midday after China’s central bank relaxed reserve requirements for its banks. The nation's own stock market struggled to overcome the cross current of other actions taken to cut down on speculative trading there, but U.S. stock markets surged at the open and had not looked back by midday. The domestic economic calendar has quiet and earnings continue to be the focal point at home, as a great number of S&P 500 companies prepare to report this week. ECONOMIC EVENTS: In the U.S., the Chicago Fed National Activity Index had a reading of -0.42, versus expectations for a +0.10 reading. A reading below zero represents economic activity below trend. In China, the People's Bank of China cut the reserve-requirement ratio, or the amount of reserves lenders need to hold, by 1 full percentage point, which was the biggest cut since the depths of the financial crisis and more than expected by economists. However, the Shanghai Composite Index still dropped 1.6%, since the reserve-requirement cut came after regulators had moved to curb speculative trading with actions taken Friday. COMPANY NEWS: Shares of Morgan Stanley (MS) advanced 1% after the bank's headline earnings excluding certain adjustments and tax benefits beat expectations. CEO James Gorman noted that the first quarter of the year was the bank's "strongest quarter in many years with improved performance across most areas of the firm." Morgan Stanley also increased its quarterly dividend to 15c per share from 10c per share. MAJOR MOVERS: Among the notable gainers was Hasbro (HAS), which gained 10% after the toymaker's sales and profits widely topped expectations in its fiscal first quarter. Also higher was Rovi (ROVI), which gained more than 10% after the company announced it has renewed its patent license and interactive program guide product agreement with Charter Communications (CHTR). Among the noteworthy losers was FARO Technologies (FARO), which dropped 25% and was downgraded by Noble Financial and Needham after the preannounced lower than expected first quarter revenue. Also lower were a number of companies that are developing CAR-T cancer therapies following the annual meeting of the American Association for Cancer Research. Mizuho analyst Peter Lawson attributed the pullback to disappointment in this weekend's solid tumor data on a small number of patients with advanced cancers who were given CAR-T therapy developed by Novartis (NVS) and the University of Pennsylvania. Shares of Kite Pharma (KITE), Juno Therapeutics (JUNO), blue bird bio (BLUE), and ZIOPHARM Oncology (ZIOP) were all lower near noon. INDEXES: Near midday, the Dow was up 236.19, or 1.32%, to 18,062.49, the Nasdaq was up 59.54, or 1.21%, to 4,991.35, and the S&P 500 was up 21.82, or 1.05%, to 2,103.00.
11:57 EDTZIOPMizuho reiterates Buy on Kite Pharma amid selloff
Subscribe for More Information
11:44 EDTZIOPCAR-T therapy stocks fall following cancer research meeting
Subscribe for More Information
April 18, 2015
20:31 EDTTHLDThreshold Pharmaceuticals to hold analyst and investor day
Subscribe for More Information
April 15, 2015
12:33 EDTZIOPStocks with call strike movement; ZIOP AVP
Ziopharm (ZIOP) October 14 call option implied volatility increased 8% to 97, Avon Products (AVP) July 11 call option implied volatility decreased 2% to 57 according to IVolatility.
05:51 EDTZIOPStocks with implied volatility movement; ZIOP MNKD
Subscribe for More Information
April 14, 2015
11:36 EDTZIOPZiopharm cancels out of two meetings, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use